Compare Abbott Laboratories (ABT) vs SOLAI Limited (SLAI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs SOLAI Limited — how do they compare? Abbott Laboratories trades at $95.6 (market cap $166.94B), while SOLAI Limited trades at $3.22 (market cap $14.40M). The key difference: Abbott Laboratories is far larger — about 11593.1× SOLAI Limited's market cap, and Abbott Laboratories pays a 2.63% dividend while SOLAI Limited pays none. Which is the better fit depends on your goals.
| ABT | SLAI | |
|---|---|---|
Market Cap | $166.94B | $14.40M |
Sector | Health | Technology |
52-Week High | $136.62 | $43.75 |
52-Week Low | $82.57 | $2.74 |
Enterprise Value | $193.69B | $14.04M |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
SLAI trades at $3.27, up 5.48% today, but faces significant financial challenges with negative profitability metrics including a -134.63% net income margin and -$33.88M net loss for 2025. The company recently completed a 7:1 reverse stock split and acquired a 51% stake in NEURALAND while receiving NYSE listing standard notices. Technical indicators show a bearish trend with support at $3 and resistance at $4.
Despite recent acquisitions and product launches, SLAI's persistent losses and negative cash flow present substantial investment risks. The single analyst covering the stock maintains a Hold rating, reflecting cautious sentiment amid ongoing financial restructuring and competitive pressures in the AI infrastructure market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About SOLAI Limited
SOLAI focuses on providing innovative AI-driven software solutions. The company leverages artificial intelligence to enhance digital experiences and optimize business processes for various industries.
Read more on SLAI →
